InflaRx

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is vilobelimab.

CEO

Niels Christoph Riedemann

CEONiels Christoph Riedemann

Employees

Employees59

Headquarters

Jena, Thueringen

HeadquartersJena, Thueringen

Founded

2007

Founded2007

Employees

Employees59

IFRX Key Statistics

Market cap

103.88M

Market cap103.88M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

57.58K

Average volume57.58K

High today

$2.67

High today$2.67

Low today

$2.28

Low today$2.28

Open price

$2.50

Open price$2.50

Volume

97.17K

Volume97.17K

52 Week high

$4.99

52 Week high$4.99

52 Week low

$0.7762

52 Week low$0.7762

IFRX Earnings

-$0.40

-$0.26

-$0.13

$0.01

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Mar 23, Pre-Market

ActualExpected Mar 23, Pre-Market

InflaRx

Why Robinhood?

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is vilobelimab. Show more

IFRX Key Statistics

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is vilobelimab.